Post-Kala-Azar Dermal Leishmaniasis
- PMID: 39043164
- PMCID: PMC11448539
- DOI: 10.4269/ajtmh.24-0018
Post-Kala-Azar Dermal Leishmaniasis
Conflict of interest statement
Authors’ contributions: A. Sharma: conceptualization, writing—original (lead), writing—revision (lead). A Bishnoi: writing—original (equal), writing—revision (equal). D. Parsad: conceptualization, writing—original (equal), writing—revision (equal), supervision.
Figures



Similar articles
-
Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.Rev Soc Bras Med Trop. 2018 Jan-Feb;51(1):105-107. doi: 10.1590/0037-8682-0487-2016. Rev Soc Bras Med Trop. 2018. PMID: 29513829
-
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12. Trop Med Int Health. 2012. PMID: 22882665
-
Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report.East Afr Med J. 2003 Aug;80(8):440-2. doi: 10.4314/eamj.v80i8.8738. East Afr Med J. 2003. PMID: 14601788
-
Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.BMC Infect Dis. 2015 Nov 23;15:543. doi: 10.1186/s12879-015-1260-x. BMC Infect Dis. 2015. PMID: 26592919 Free PMC article. Review.
-
Treatment of leishmaniasis with miltefosine: 2008 status.Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209. Expert Opin Drug Metab Toxicol. 2008. PMID: 18721114 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources